The same disparity between rich animal data and sparse human trials characterizes many peptide compounds, partly because the economics of pharmaceutical development disfavor compounds that cannot be patented in their natural form
Phase 3 ACHIEVE-1 trial results for orforglipron, as discussed by Rosenstock and colleagues, demonstrated that this once-daily oral small molecule GLP-1 achieved statistically significant reductions in HbA1c (1.3% to 1.6% from a baseline of 8.0%) compared to placebo in adults with type 2 diabetes
Kaileras peers (Aktis, Eikon, Caris, etc.) all fit the well-capitalized, late-stage pipeline, deep-pocketed backers mold ( [66] ) ( [2] )
Our specially formulated multivitamins for bariatric patients are designed to meet the unique nutritional needs of post-surgery individuals, helping you maintain optimal health
New England Journal of Medicine , 391 (13), 11931205